Subtype
Malignant Anorectal Neoplasm
CI-CAN-00005864Explore in graph →
452 active trials1 approved drugs6 evidence items
- NCIt
- C215225
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00005864Explore in graph →
Clinical trials
1,783 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (174)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06056804 | Neoadjuvant Chemoradiotherapy Combined With PD-1 Inhibitor and Thymalfasin for pMMR/MSS Locally Advanced Mid-low Rectal Cancer | active not recruiting | Phase 2 | 20 | Beijing Friendship HospitalOTHER | 1 | Apr 2, 2025 | clinicaltrials |
| NCT04802876 | Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing Tumors(ACROPOLI) | active not recruiting | Phase 2 | 184 | SOLTI Breast Cancer Research GroupOTHER | 1 |
| Mar 21, 2025 |
| clinicaltrials |
| NCT00200200 | Hepatic Arterial Infusion With Floxuridine and Dexamethasone Combination With Chemotherapy With/Without Bevacizumab for Hepatic Metastases From Colorectal Cancer | completed | Phase 2 | 73 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Mar 19, 2025 | clinicaltrials |
| NCT06872606 | Short-Course Radiotherapy Combined with Intracavitary Brachytherapy Followed by Pucotenlimab, Bevacizumab, Oxaliplatin, and Trifluridine/Tipiracil (TAS-102) for Total Neoadjuvant Therapy of Microsatellite Stable (MSS) Locally Advanced Low Rectal Cancer(SCRIPBOT) | not yet recruiting | Phase 2 | 33 | Sir Run Run Shaw HospitalOTHER | 1 | Mar 12, 2025 | clinicaltrials |
| NCT01643070 | Preoperative CRT With or Without Induction Chemotherapy for Rectal Cancer With Liver Metastases | completed | Phase 2 | 38 | Asan Medical CenterOTHER | 1 | Feb 25, 2025 | clinicaltrials |
| NCT04380337 | Organ Preservation Program Using Short-Course Radiation & FOLFOXIRI in Rectal Cancer | completed | Phase 2 | 38 | Stanford UniversityOTHER | 1 | Feb 25, 2025 | clinicaltrials |
| NCT06840665 | MR-guided Adaptive Radiotherapy Combined With PD-1 Antibody and CAPOX for Locally Advanced Rectal Cancer | recruiting | Phase 2 | 46 | Fudan UniversityOTHER | 1 | Feb 21, 2025 | clinicaltrials |
| NCT04357873 | Efficacy of Immunotherapy Plus a Drug in Patients With Progressive Advanced Mucosal Cancer of Different Locations(PEVOsq) | completed | Phase 2 | 112 | UNICANCEROTHER | 1 | Feb 19, 2025 | clinicaltrials |
| NCT06812728 | Neoadjuvant FOLFIRINOX and Preoperative Chemoradiotherapy for Locally Advanced Rectal Cancer Patients | recruiting | Phase 2 | 100 | Menoufia UniversityOTHER | 1 | Feb 19, 2025 | clinicaltrials |
| NCT04696757 | Non-OpeRative MANagement of Rectal Cancer Patients(NORMANDY) | completed | Phase 2 | 18 | Kangbuk Samsung HospitalOTHER | 1 | Feb 12, 2025 | clinicaltrials |
| NCT01652196 | Aflibercept and FOLFOX6 Treatment for Previously Untreated Stage IV Colorectal Cancer | completed | Phase 2 | 56 | John HaysOTHER | 1 | Feb 5, 2025 | clinicaltrials |
| NCT01814501 | Panitumumab and Chemotherapy in Patients With Advanced Colorectal Cancer After Prior Therapy With Bevacizumab | completed | Phase 2 | 16 | John HaysOTHER | 1 | Feb 5, 2025 | clinicaltrials |
| NCT05792735 | Neoadjuvant Cadonilimab Plus Chemotherapy Following Short-Course Radiotherapy in Locally Advanced Rectal Cancer(NeoCaCRT) | completed | Phase 2 | 27 | Shenzhen People's HospitalOTHER | 1 | Feb 5, 2025 | clinicaltrials |
| NCT06802666 | Short-course Radiotherapy Followed by AK112 and CAPOX as Neoadjuvant Therapy for Locally Advanced Rectal Cancer | recruiting | Phase 2 | 45 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Jan 31, 2025 | clinicaltrials |
| NCT02000050 | Phase II Study of Up-front Chemotherapy and Neo-adjuvant Short-course Radiotherapy for Resectable Rectal Carcinoma (COLORE)(COLORE) | completed | Phase 2 | 52 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSOTHER | 1 | Jan 30, 2025 | clinicaltrials |
| NCT06793137 | Intestinal Microbiome Modulation With Antibiotics in the Neoadjuvant Treatment of Locally Advanced Rectal Cancer | recruiting | Phase 2 | 100 | AC Camargo Cancer CenterOTHER | 1 | Jan 29, 2025 | clinicaltrials |
| NCT06108596 | Evaluation of the Efficacy and Safety of Interleucin-2 Combined With PD-1 Monoclonal Antibody and CAPOX in Preoperative Neoadjuvant Therapy for Mid-low Locally Advanced Rectal Cancer - a Single-center, Single-arm, Open-label Clinical Trail(PICS) | completed | Phase 2 | 33 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jan 21, 2025 | clinicaltrials |
| NCT06783153 | Efficacy and Safety of Adjunctive Use of Rifaximin In Preventing Radiotherapy-induced Diarrhea in Cancer Patients | not yet recruiting | Phase 1 / Phase 2 | 80 | Mansoura UniversityOTHER | 1 | Jan 20, 2025 | clinicaltrials |
| NCT04518280 | Short-course Radiotherapy Based TNT Combined With PD-1 Inhibitor for Locally Advanced Rectal Cancer(TORCH) | completed | Phase 2 | 130 | Fudan UniversityOTHER | 1 | Jan 17, 2025 | clinicaltrials |
| NCT06765616 | Adebrelimab Injection (PD-L1) Combined With Short Course Radiotherapy and Chemotherapy for Neoadjuvant Therapy of Locally Advanced Rectal Cancer | recruiting | Phase 2 | 31 | Feng TianOTHER_GOV | 1 | Jan 9, 2025 | clinicaltrials |
| NCT06760520 | Short-course Radiotherapy Followed by CAPOX and Ivonescimab for Locally Advanced Rectal Cancer | not yet recruiting | Phase 2 | 40 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 0 | Jan 8, 2025 | clinicaltrials |
| NCT06751394 | Preoperative Chemoradiotherapy and Toripalimab in Locally Recurrent Rectal Cancer(TRACER) | not yet recruiting | Phase 2 | 44 | Sixth Affiliated Hospital, Sun Yat-sen UniversityOTHER | 1 | Dec 27, 2024 | clinicaltrials |
| NCT05601505 | Circulating Tumor DNA-guided Neoadjuvant Treatment Strategy for Locally Advanced Rectal Cancer(CINTS-R) | recruiting | Phase 2 | 470 | Peking Union Medical College HospitalOTHER | 1 | Dec 24, 2024 | clinicaltrials |
| NCT04719988 | Anti-PD-1 and mDCF Followed by Chemoradiotherapy in Patients With Stage III Squamous Cell Anal Carcinoma.(INTERACT-ION) | active not recruiting | Phase 2 | 55 | Centre Hospitalier Universitaire de BesanconOTHER | 1 | Dec 20, 2024 | clinicaltrials |
| NCT02861300 | CB-839 + Capecitabine in Solid Tumors and Fluoropyrimidine Resistant PIK3CA Mutant Colorectal Cancer | completed | Phase 1 / Phase 2 | 50 | David Bajor, MDOTHER | 1 | Dec 19, 2024 | clinicaltrials |
| NCT06542588 | Short-Course Radiotherapy Followed by Neoadjuvant Chemotherapy, HLX07and Serplulimab in LARC | recruiting | Phase 2 | 29 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Dec 18, 2024 | clinicaltrials |
| NCT05060471 | PD-1 Blockade Combined With Chemotherapy Followed by Concurrent Immunoradiotherapy for Locally Advanced SCCA Patients | completed | Phase 2 | 25 | Sun Yat-sen UniversityOTHER | 1 | Dec 3, 2024 | clinicaltrials |
| NCT03436563 | M7824 in Patients With Metastatic Colorectal Cancer or With Advanced Solid Tumors With Microsatellite Instability | completed | Phase 1 / Phase 2 | 4 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 27, 2024 | clinicaltrials |
| NCT06575725 | Botensilimab, Balstilimab and Regorafenib or Botensilimab and Balstilimab for the Treatment of Advanced or Metastatic Microsatellite Stable Colorectal Cancer | withdrawn | Phase 2 | 0 | City of Hope Medical CenterOTHER | 0 | Nov 21, 2024 | clinicaltrials |
| NCT06530303 | Biological Tumor Infiltrating Lymphocytes Therapy With Immunotherapy for Colon and Rectum Cancer(BAH248) | recruiting | Phase 1 / Phase 2 | 85 | Essen BiotechOTHER | 1 | Nov 5, 2024 | clinicaltrials |
| NCT06665087 | CGA Guided Ultrafractionated RT and First-line Systemic Treatment in Elderly or Frail Patients with MCRC | not yet recruiting | Phase 2 | 110 | Fudan UniversityOTHER | 0 | Oct 30, 2024 | clinicaltrials |
| NCT06652412 | CGA Guided Ultrafractionated RT and Systemic Treatment in Elderly or Frail Patients with Inoperable Localized CRC | not yet recruiting | Phase 2 | 124 | Fudan UniversityOTHER | 0 | Oct 28, 2024 | clinicaltrials |
| NCT00807911 | Adjuvant Chemotherapy After Preoperative Chemoradiotherapy to Treat Rectal Cancer | completed | Phase 2 | 322 | Asan Medical CenterOTHER | 1 | Oct 23, 2024 | clinicaltrials |
| NCT05628038 | The Combination of Hypofractionated Radiotherapy and Immunotherapy in Locally Recurrent Rectal Cancer(TORCH-R) | recruiting | Phase 2 | 93 | Fudan UniversityOTHER | 1 | Oct 1, 2024 | clinicaltrials |
| NCT05356897 | Tucatinib Combined with Trastuzumab and TAS-102 for the Treatment of HER2 Positive Metastatic Colorectal Cancer in Molecularly Selected Patients, 3T Study | withdrawn | Phase 2 | 0 | Academic and Community Cancer Research UnitedOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06599827 | Neoadjuvant Moderately Hypofractionated Radiotherapy Combined with Chemotherapy and Immunotherapy for High-risk LARC(iMHRT-LARC) | not yet recruiting | Phase 2 | 54 | Shanghai Zhongshan HospitalOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT02431676 | Survivorship Promotion In Reducing IGF-1 Trial(SPIRIT) | completed | Phase 2 | 121 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Aug 28, 2024 | clinicaltrials |
| NCT05086627 | Short-course Radiotherapy Followed by Tislelizumab + CapeOX in the Treatment for Locally Advanced Rectal Cancer | completed | Phase 2 | 118 | Hebei Medical University Fourth HospitalOTHER | 1 | Aug 22, 2024 | clinicaltrials |
| NCT06006390 | CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 60 | Chongqing Precision Biotech Co., LtdINDUSTRY | 1 | Aug 9, 2024 | clinicaltrials |
| NCT00788957 | Panitumumab Combination Study With Rilotumumab or Ganitumab in Wild-type Kirsten Rat Sarcoma Virus Oncogene Homolog (KRAS) Metastatic Colorectal Cancer (mCRC) | completed | Phase 1 / Phase 2 | 177 | NantBioScience, Inc.INDUSTRY | 0 | Aug 7, 2024 | clinicaltrials |
| NCT04636008 | Sintilimab Plus Hypofractionated Radiotherapy for MSI-H/dMMR Rectal Cancer | unknown | Phase 1 / Phase 2 | 20 | West China HospitalOTHER | 1 | Aug 6, 2024 | clinicaltrials |
| NCT06505551 | Phase 1/2 Study of Autologous SCG142 TCR T Cells in Patients With HPV16/52-positive Carcinoma | not yet recruiting | Phase 1 / Phase 2 | 66 | SCG Cell Therapy Pte. Ltd.INDUSTRY | 0 | Jul 17, 2024 | clinicaltrials |
| NCT03439085 | DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine INO-3112 and Durvalumab in Treating Patients With Recurrent or Metastatic Human Papillomavirus Associated Cancers | terminated | Phase 2 | 41 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 9, 2024 | clinicaltrials |
| NCT06455124 | Short-course Radiotherapy Combined With CapeOx and PD-1 Inhibitor After Local Excision for High-risk Early Rectal Cancer (TORCH-LE) | recruiting | Phase 2 | 60 | Fudan UniversityOTHER | 1 | Jun 13, 2024 | clinicaltrials |
| NCT06443671 | Neoadjuvant Fruquintinib Plus Tislelizumab Combined With mCapeOX Versus CapeOX for Mid-high pMMR/MSS Locally Advanced Rectal Cancer(PKUCH-R09) | not yet recruiting | Phase 2 / Phase 3 | 132 | Peking University Cancer Hospital & InstituteOTHER | 1 | Jun 5, 2024 | clinicaltrials |
| NCT03992456 | Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer | unknown | Phase 2 | 12 | Academic and Community Cancer Research UnitedOTHER | 1 | May 21, 2024 | clinicaltrials |
| NCT04755920 | SGM-101 in Colorectal Brain Metastases.(SGM-CBM) | unknown | Phase 2 | 10 | Leiden University Medical CenterOTHER | 1 | May 9, 2024 | clinicaltrials |
| NCT06395337 | Multimodal Imaging in Rectal Cancer & Pancreatic Cancer(MIRCA & MIPAC) | unknown | Phase 1 / Phase 2 | 20 | Radboud University Medical CenterOTHER | 1 | May 2, 2024 | clinicaltrials |
| NCT04205955 | Testing Diet Intervention Versus Non-Diet Intervention for Management of Bowel Symptoms in Rectal Cancer Survivors | completed | Phase 2 | 95 | SWOG Cancer Research NetworkNETWORK | 2 | May 1, 2024 | clinicaltrials |
| NCT06390982 | Organ Preservation With Tislelizumab and Total Neoadjuvant Therapy in Patients With Low Rectal Cancer: RELIEVE -01 Study | not yet recruiting | Phase 2 | 46 | Fudan UniversityOTHER | 0 | Apr 30, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Apr 2, 2025source: clinicaltrials